- Patient/Guest
- Phlebotomist
- Updates
| Apo A1 B | - |
|---|
|
Measure apolipoproteins A1 and B |
||
 |
Synonym | See updates |
 |
Test Code | CDBIOPR0035 |
 |
Test Type | Biochemistry |
 |
Pre-Test Condition | See updates |
 |
Report Availability | 2 D(s) |
 |
# Test(s) | Multiple |
| Test details | Sample Report |
|---|---|
| Apo A1 B |
|
|
Synonym | See updates | |
|
Test Code | CDBIOPR0035 | |
 |
Test Category | Cardiovascular disorders | |
|
Pre-Test Condition | See updates | |
 |
Medical History | See updates | |
|
Report Availability | 2 D(s) | |
 |
Specimen/Sample | Serum; 2 mL; SST | |
 |
Stability @21-26 deg. C | 6 Hr(s) | |
 |
Stability @ 2-8 deg. C | 7 D(s) | |
 |
Stability @ Frozen | 1 M(s) | |
|
# Test(s) | Multiple | |
 |
Processing Method | Nephelometry | |
| **Apolipoproteins A1 and B****FDA Status**: Standard laboratory procedure under CLIA; no specific FDA approval required.**Other Names**: Apo A1/B Test, Lipid Risk Panel.**Historical Breakthrough**: Developed in the 1980s to assess cardiovascular risk, advancing cardiology.**Key Purpose and Impact**: Measures Apo A1 and Apo B to evaluate cardiovascular risk more precisely than standard lipid profiles.**Preparation and Patient History**: Fasting blood; report heart disease history or lipid therapy.**Consent Requirement**: Standard consent for diagnostic testing.**Clinical Value**: Sensitivity ~95%; specificity ~95%; detects risk in ~85% of cases; guides therapy.**References Cited**: Testing.com Lipid Tests 2023; Labcorp Apolipoprotein Test 2025; UpToDate Dyslipidemia 2025 |